Fennec Pharmaceuticals Inc
FENC
Get informed when a big investor buys or sells
+ FollowMarket Cap$430.39M
Close$
$-10.89
193.5% downside
Current Fair Value
193.5% downsideOvervalued by 193.5% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $430.39 Million |
|---|---|
| Enterprise Value | $392.32 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.36 |
| Beta | 1.07 |
| Outstanding Shares | 34,545,000 |
Return
| Return on Equity | -8.69% |
|---|---|
| Return on Assets | -4.87% |
| Return on Invested Capital | -2.70% |
Valuation & Multiples
| P/E Ratio | -95.31 |
|---|---|
| PEG | 58.62 |
| Price to Sales | 11.65 |
| Price to Book Ratio | 11.65 |
| Enterprise Value to Revenue | 6.6 |
| Enterprise Value to EBIT | -229.38 |
| Enterprise Value to Net Income | -107 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | 0.07 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 13, 2026
EPS Estimate
$0.02
Average shareholder expectationRevenue Estimate
$16.21 M
Average shareholder expectationNext Earnings Call
Expected Date
November 5, 2026
EPS Estimate
$0.10
Average shareholder expectationRevenue Estimate
$19.11 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | 35,200▲ 57.14% |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 47.45%▲ 0.26% |
|---|---|
| Total Invested | $176.25M▲ 76.88% |
| Investors Holding | 108▲ 17.00% |
ESG Score
No data
About Fennec Pharmaceuticals Inc
CEO: Rostislav Raykov